• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial
【2h】

Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial

机译：比较重度抑郁症患者早期药物变更（EMC）策略与常规治疗（TAU）的随机临床试验的原理和设计-EMC试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundIn Major Depressive Disorder (MDD), the traditional belief of a delayed onset of antidepressants' effects has lead to the concept of current guidelines that treatment durations should be between 3-8 weeks before medication change in case of insufficient outcome. Post hoc analyses of clinical trials, however, have shown that improvement usually occurs within the first 10-14 days of treatment and that such early improvement (Hamilton Depression Rating Scale [HAMD] decrease ≥20%) has a substantial predictive value for final treatment outcome. Even more important, non-improvement (HAMD decrease <20%) after 14 days of treatment was found to be highly predictive for a poor final treatment outcome.
机译：背景在重度抑郁症（MDD）中，传统的抗抑郁药作用延迟发作的观念导致了当前指南的概念，即如果结果不足，则治疗时间应在药物更换前3-8周之间。然而，对临床试验的事后分析表明，改善通常发生在治疗的最初10-14天内，而且这种早期改善（汉密尔顿抑郁量表[HAMD]降低≥20％）对于最终治疗具有重大的预测价值结果。更为重要的是，发现治疗14天后未改善（HAMD降低<20％）对最终治疗效果差有很高的预测作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号